Catalyst Pharmaceuticals Inc
NASDAQ:CPRX

Watchlist Manager
Catalyst Pharmaceuticals Inc Logo
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Watchlist
Price: 21.23 USD -2.08%
Market Cap: 2.5B USD
Have any thoughts about
Catalyst Pharmaceuticals Inc?
Write Note

Operating Margin
Catalyst Pharmaceuticals Inc

19.8%
Current
35%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
19.8%
=
Operating Profit
85.9m
/
Revenue
434.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
2.6B USD
20%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
142B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country US
Market Cap 2.6B USD
Operating Margin
20%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.2B USD
Operating Margin
28%
Country US
Market Cap 142B USD
Operating Margin
19%
Country US
Market Cap 115B USD
Operating Margin
38%
Country US
Market Cap 101.6B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78.5B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Catalyst Pharmaceuticals Inc
Glance View

Market Cap
2.5B USD
Industry
Biotechnology
Economic Moat
Wide

Catalyst Pharmaceuticals Inc., a biopharmaceutical company founded with a determined focus on developing innovative therapies, has systematically carved out a niche in the treatment of rare neuromuscular and neurological diseases. Headquartered in Coral Gables, Florida, the company emerged as a lifeline for patients grappling with these debilitating conditions, particularly targeting those with limited treatment options. At the heart of Catalyst’s business model is its flagship product, Firdapse (amifampridine), a pioneering medication approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). This niche focus allows Catalyst to not only address unmet medical needs but also to navigate a less crowded competitive landscape, where larger pharmaceutical giants often overlook rare conditions. Catalyst Pharmaceuticals' revenue stream is primarily derived from the commercial sales of Firdapse, which has gained traction in the rare disease market due to its status as a first-line treatment. The company adopts a strategic approach by exclusively concentrating on rare diseases, benefiting from incentives such as orphan drug designations, which often include extended market exclusivity, tax credits, and potential grants. This strategy is bolstered by an experienced management team that adeptly leverages Catalyst’s research capabilities and regulatory know-how, ensuring a robust pipeline poised for future growth. By maintaining strong relationships with healthcare providers and patient advocacy groups, Catalyst Pharmaceuticals reinforces its commitment to patient-centric solutions, enabling both sustained market presence and organic growth within its specialized field.

CPRX Intrinsic Value
23.46 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
19.8%
=
Operating Profit
85.9m
/
Revenue
434.5m
What is the Operating Margin of Catalyst Pharmaceuticals Inc?

Based on Catalyst Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 19.8%.